title: [Chemotherapy for non-small cell lung cancer: split-dose administration of Cisplatin over four consecutive days and Vinorelbine ditartrate].
abstract: OBJECTIVE
  At present, combination chemotherapy with Cisplatin (CDDP) and Vinorelbine ditartrate (VNR) is one of the standard regimens for non-small cell lung cancer (NSLC). To avoid renal damage by CDDP, hydration and diuretic are indicated. But elderly/postoperative patients who have reduced lung vessel capacity are a high-risk group for pulmonary edema/right heart failure by hydration. In our hospital, CDDP is administered on four consecutive days without large hydration.
  
  
  METHODS
  CDDP: 80 mg/m2 (over four consecutive days)without large hydration+VNR: 20 mg/m2 was administered 30 NSLC patients(Stage III A & IV). Serum concentration of CDDP was monitored.
  
  
  RESULTS
  Response rate was CR: 0 case; PR: 9 cases; SD: 16 cases; PD: 5 cases. Mean survival time (MST) was 292 days. The efficacy and prognosis are equivalent to a conventional CDDP+VNR regimen. On the other hand, side effects were reduced; neutrocytopenia (> Grade 3): 17%, renal dysfunction (>Grade 1): 17%. Mean serum concentrations of CDDP were accumulated day by day, 0.91 microg/mL(Day 1), 2.44 microg/mL(Day 4), but were all under the toxic threshold(8 microg/mL).
  
  
  CONCLUSIONS
  Our regimen (CDDP given over four consecutive days without large hydration) may become a regimen for the high-risk patient.
authors.affiliation: Dept. of Surgery, Shimonoseki City Central Hospital.
authors.forename: Koichi
authors.initials: K
authors.lastname: Furugaki
authors.forename: Junichi
authors.initials: J
authors.lastname: Yoshida
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Ogawa
authors.forename: Iori
authors.initials: I
authors.lastname: Nagamatsu
authors.forename: Masafumi
authors.initials: M
authors.lastname: Miura
authors.forename: Koji
authors.initials: K
authors.lastname: Hokazono
authors.forename: Shuyo
authors.initials: S
authors.lastname: Umeda
authors.forename: Masahiro
authors.initials: M
authors.lastname: Shinohara
authors.forename: Masaharu
authors.initials: M
authors.lastname: Ekimura
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Ishimaru
authors.forename: Yuko
authors.initials: Y
authors.lastname: Okamoto
authors.forename: Nobumichi
authors.initials: N
authors.lastname: Ogami
authors.forename: Sakae
authors.initials: S
authors.lastname: Nagaoka
authors.forename: Kazumi
authors.initials: K
authors.lastname: Ebe
authors.forename: Takuya
authors.initials: T
authors.lastname: Emoto
authors.forename: Asuka
authors.initials: A
authors.lastname: Seto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Sugihara
authors.forename: Junko
authors.initials: J
authors.lastname: Yukawa
authors.forename: Kenichi
authors.initials: K
authors.lastname: Matsuo
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine